What is EnginZyme?
EnginZyme operates at the intersection of biotechnology and industrial chemistry, positioning itself as a leader in the sustainable manufacturing sector. The company utilizes a patented cell-free technology platform that leverages nature’s catalysts—enzymes—to optimize chemical processes. By replacing conventional, energy-intensive manufacturing with biobased alternatives, EnginZyme provides a scalable solution for industries seeking to reduce their environmental footprint. The firm's core value proposition lies in its ability to combine the precision of biology with the efficiency of the chemical industry, offering a best-of-both-worlds approach to modern production challenges.
How much funding has EnginZyme raised?
EnginZyme has raised a total of $35.3M across 2 funding rounds:
Series A
$13M
Series B
$22.3M
Series A (2021): $13M with participation from Sofinnova Partners, Industrifonden, and SEB Greentech
Series B (2022): $22.3M led by Sofinnova Partners and Industrifonden
Key Investors in EnginZyme
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder, partnering with entrepreneurs from seed to later-stage to develop transformative innovations.
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies. They focus on deep tech and life sciences, providing long-term support to ventures with the potential to change industries.
SEB Greentech
SEB Greentech is an investment arm focused on supporting sustainable technologies and green innovations that drive the transition to a low-carbon economy.
What's next for EnginZyme?
With the successful closure of this major enterprise-level funding, EnginZyme is well-positioned to accelerate the commercialization of its biobased manufacturing platform. The strategic roadmap likely involves expanding production capacity and deepening partnerships across diverse industrial sectors that rely on complex chemical synthesis. As the company moves beyond its current scaling phase, the focus will shift toward achieving broader market penetration and proving the long-term economic viability of its cell-free technology at an industrial scale. Investors remain optimistic that EnginZyme will continue to serve as a pivotal player in the global shift toward sustainable, high-performance manufacturing.
See full EnginZyme company page
